Why diversity is needed at every level of clinical trials, from participants to leaders

Khadijah Breathett

DOI: https://doi.org/10.1038/s41591-024-02914-x

IF: 82.9

2024-04-12

Nature Medicine

Abstract:Diversity in clinical trials must be accompanied by justice and equity, including benefits for underrepresented participants, in order to boost population health.

biochemistry & molecular biology,cell biology,medicine, research & experimental

What problem does this paper attempt to address?

Enhancing Diversity and Inclusion in Clinical Trials

Amy Corneli,Emily Hanlen‐Rosado,Kevin McKenna,Richardae Araojo,Dawn Corbett,Kaveeta Vasisht,Bernadette Siddiqi,Tesheia Johnson,Luther T. Clark,Sara B. Calvert

DOI: https://doi.org/10.1002/cpt.2819

2023-01-11

Clinical Pharmacology & Therapeutics

Abstract:Women and people from most racial and ethnic groups in the United States have historically been under-represented in clinical trials of investigational medical products. Inadequate representation of these groups may lead to an incomplete understanding of the safety and efficacy of new drugs, devices, biologics, and vaccines, and limit the generalizability of trial findings. As a result, new medical products may not be beneficial to all people who need them, and existing inequities in outcomes among various population groups may remain unchanged or worsen, or new disparities may arise. Although much work has focused on study-level strategies, research organizations must make systemic changes to how clinical trials are envisioned and implemented to achieve sustainable support for diversity and inclusion in clinical trials. The Clinical Trials Transformation Initiative (CTTI) conducted interviews with leaders at institutions that conduct clinical trials to explore perspectives on organizational-level practices that promote diversity and inclusion in clinical trials. Leaders described motivations, such as an ethical and moral imperative; organizational practices, such as staff investment and resource allocation; perceived return on investments, such as better science; and deterrents, such as cost and time. The CTTI also convened an expert meeting to discuss the interview findings and provide guidance. We present the interview findings and expert guidance in a framework that describes four key areas-commitment, partnerships, accountability, and resources-on sustaining organizational-level approaches for improving diversity and inclusion in clinical trials, with the ultimate goal of advancing health equity. Institutions who conduct and support clinical trials should implement organizational-level approaches to improve equitable access and diverse patient participation in clinical trials.

pharmacology & pharmacy
On improving clinical trial diversity: Viewpoints from underrepresented breast cancer survivors.

Kimberley T Lee,Rebecca M. Blackwell,Melinda Leigh Maconi,Carley Geiss,Susan Thomas Vadaparampil,Brian D. Gonzalez,Heather S.L. Jim,Clement K Gwede,Hatem Hussein Soliman

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e13674

IF: 45.3

2024-05-31

Journal of Clinical Oncology

Abstract:e13674 Background: Racial and ethnic diversity in cancer clinical trials remains low. In this formative work, we sought to better characterize patient attitudes towards clinical trial participation. The goal is to build a framework that can be leveraged to develop an intervention to increase enrollment of participants from racial and ethnic minority groups in clinical trials. Methods: Semi-structured interviews were conducted with 10 Black and 10 Hispanic breast cancer survivors receiving care at a comprehensive cancer center in the South. Interviews were recorded, transcribed verbatim, and coded using thematic analysis. Results: Patient attitudes to clinical trials were generally positive. Many felt that trials were beneficial and a necessary part of advancing medical science. However, many expressed hesitations with regards to trial participation due to safety and efficacy concerns and distrust regarding motivation of healthcare system. Facilitators of positive attitudes towards clinical trials included positive social circles including family and community, as well as altruism regarding supporting racial and ethnic diversity in clinical trials. Conclusions: Collectively, these findings underscore the importance of implementing strategies to foster diversity in the biomedical research community, community outreach, and lay education, to improve trust in the system and therefore attitudes towards clinical trial participation in minority populations. [Table: see text]

oncology
Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representatives

Robin Chatters,Munyaradzi Dimairo,Cindy Cooper,Shamila Ditta,Jonathan Woodward,Katie Biggs,Della Ogunleye,Fiona Thistlethwaite,Christina Yap,Alexander Rothman,Chatters,R.,Dimairo,M.,Cooper,C.,Ditta,S.,Woodward,J.,Biggs,K.,Ogunleye,D.,Thistlethwaite,F.,Yap,C.,Rothman,A.

DOI: https://doi.org/10.1136/bmjopen-2023-075547

IF: 3.006

2024-03-20

BMJ Open

Abstract:Objectives To explore the importance of, and barriers to achieving, diversity in early-phase clinical trials. Design Qualitative interviews analysed using thematic analysis. Setting and participants Five professionals (clinical researchers and methodologists) and three patient and public representatives (those with experience of early-phase clinical trials and/or those from ethnic minority backgrounds) were interviewed between June and August 2022. Participants were identified via their institutional web page, existing contacts or social media (eg, X, formerly known as Twitter). Results Professionals viewed that diversity is not currently considered in all early-phase clinical trials but felt that it should always be taken into account. Such trials are primarily undertaken at a small number of centres, thus limiting the populations they can access. Referrals from clinicians based in the community may increase diversity; however, those referred are often not from underserved groups. Referrals may be hindered by the extra resources required to approach and recruit underserved groups and participants often having to undertake 'self-driven' referrals. Patient and public representatives stated that diversity is important in research staff and that potential participants should be informed of the need for diversity. Those from underserved groups may require clarification regarding the potential harms of a treatment, even if these are unknown. Education may improve awareness and perception of early-phase clinical trials. We provide 14 recommendations to improve diversity in early-phase clinical trials. Conclusions Diversity should be considered in all early-phase trials. Consideration is required regarding the extent of diversity and how it is addressed. The increased resources needed to recruit those from underserved groups may warrant funders to increase the funds to support the recruitment of such participants. The potential harms and societal benefits of the research should be presented to potential participants in a balanced but accurate way to increase transparency.

medicine, general & internal
Diversity, Equity, and Inclusion in Clinical Research: A Path Toward Precision Health for Everyone

Vindell Washington,Joseph B. Franklin,Erich S. Huang,Jessica L. Mega,Amy P. Abernethy

DOI: https://doi.org/10.1002/cpt.2804

2022-12-15

Clinical Pharmacology & Therapeutics

Abstract:Healthcare disparities are a persistent societal problem. One of the contributing factors to this status quo is the lack of diversity and representativeness of research efforts, which result in nongeneralizable evidence that, in turn, provides suboptimal means to enable the best possible outcomes at the individual level. There are several strategies that research teams can adopt to improve the diversity, equity, and inclusion (DEI) of their efforts; these strategies span the totality of the research path, from initial design to the shepherding of clinical data through a potential regulatory process. These strategies include more intentionality and DEI-based goal-setting, more diverse research and leadership teams, better community engagement to set study goals and approaches, better tailored outreach interventions, decentralization of study procedures and incorporation of innovative technology for more flexible data collection, and self-surveillance to identify and prevent biases. Within their remit of overlooking research efforts, regulatory authorities, as stakeholders, also have the potential for a positive effect on the DEI of emerging clinical evidence. All these are implementable tools and mechanisms that can make study participation more approachable to diverse communities, and ultimately generate evidence that is more generalizable and a conduit for better outcomes. The research community has an imperative to make DEI principles key foundational aspects in study conduct in order to pursue better personalized medicine for diverse patient populations.

pharmacology & pharmacy
Inclusion and diversity in clinical trials: Actionable steps to drive lasting change

Michelle D Kelsey,Bray Patrick-Lake,Raolat Abdulai,Uli C Broedl,Adam Brown,Elizabeth Cohn,Lesley H Curtis,Chris Komelasky,Michael Mbagwu,George A Mensah,Robert J Mentz,Amesika Nyaku,Stephanie O Omokaro,Judy Sewards,Kendal Whitlock,Xinzhi Zhang,Gerald S Bloomfield

DOI: https://doi.org/10.1016/j.cct.2022.106740

Abstract:Background: Improving diversity in clinical trials is essential in order to produce generalizable results. Although the importance of representation has become increasingly recognized, identifying strategies to approach this work remains elusive. This article reviews the proceedings of a multi-stakeholder conference about the current state of diversity in clinical trials and outlines actionable steps for improvement. Methods: Conference attendees included representatives from the United States Food and Drug Administration (FDA), National Institutes of Health (NIH), practicing clinical investigators, pharmaceutical and device companies, community-based organizations, data analytics companies, and patient advocacy groups. At this virtual event, attendees were asked to consider key questions around best practices for engagement of underrepresented populations. Results: Community engagement is an integral part of recruitment and retention of underrepresented groups. Decentralization of sites and use of digital tools can enhance the accessibility of clinical research. Finally, improving representation among investigators and clinical research staff may translate to diverse clinical trial participants. Conclusion: Improving diversity in clinical trials is an ethical and scientific imperative, which requires a multifaceted approach.
Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel

Bhavana Pothuri,Premal Thaker,Adrienne Moore,Rosa Espinosa,Kara Medina,Deborah Collyar,Kathleen Lutz,Mihaela C Munteanu,Brian Slomovitz

DOI: https://doi.org/10.1136/ijgc-2024-005751

2024-09-13

Abstract:Lack of patient diversity in clinical trial enrollment remains an obstacle to achieving equitable healthcare outcomes. Under-representation has resulted in non-generalizable clinical knowledge, inequitable access to treatment, and health disparities among minority and disadvantaged groups. A multidisciplinary panel was convened to consider the challenges of diverse patient accrual and provide actionable solutions to improve representation in clinical trials. The panel was comprised of participants with knowledge in gynecologic oncology and included physician, advanced practice nurse, patient navigator, patient advocate, and pharmaceutical industry representation. Focus was given to recruitment barriers for Asian and Hispanic patients. The panel identified several areas of concern, including explicit and implicit biases for the physician and care teams, language and cultural nuances, inadequate inclusion of family in the decision-making process, and under-representation of women in clinical trials. The panel also identified the important role patient navigators, nurses, and advanced practice providers have in patient recruitment from under-represented populations. The role of study sponsors, and global and regional initiatives, to address historic disparities in clinical trial recruitment were also considered critical. The actionable solutions proposed should enable study sponsors and clinical trial sites to achieve greater diversity in enrollment globally.
Clinical Trial Access in Diverse Populations

Tareefe Montaque,John Stewart

DOI: https://doi.org/10.1002/jso.28010

2024-11-28

Journal of Surgical Oncology

Abstract:Despite the disproportionate impact of cancer on minority groups, their participation in oncologic clinical trials remains low. Contributing factors include mistrust of the medical establishment, structural barriers, and implicit bias. Strategies to improve access and representation include pragmatic trial designs, patient navigation programs, financial support, and increasing diversity among medical professionals. Addressing these issues is crucial for ensuring equitable healthcare delivery and improving outcomes for underrepresented populations in clinical research.

oncology,surgery
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers

L. Vidal,Z. Dlamini,S. Qian,P. Rishi,M. Karmo,N. Joglekar,S. Abedin,R.A. Previs,C. Orbegoso,C. Joshi,H.A. Azim,H. Karkaria,M. Harris,R. Mehrotra,M. Berraondo,G. Werutsky,S. Gupta,N. Niikura,I. Chico,K.S. Saini

DOI: https://doi.org/10.1016/j.esmoop.2024.103373

IF: 6.883

2024-05-10

ESMO Open

Abstract:Some races, ethnicities, geographies, genders, ages, abilities, and economic classes are underrepresented in cancer trials. There is strong scientific and ethical rationale for inclusiveness, equity, and diversity in cancer trial populations. Stakeholders including regulators, sponsors, CROs, patient groups, and oncology journals are advocating for such diversity. Cancer trials should answer scientific questions of relevance to the diverse participating subgroups. The burden of cancer exerts a disproportionate impact across different regions and population subsets. Disease-specific attributes, coupled with genetic and socioeconomic factors, significantly influence cancer treatment outcomes. Precision oncology promises the development of safe and effective options for specific ethnic phenotypes and clinicodemographic profiles. Currently, clinical trials are concentrated in resource-rich geographies with younger, healthier, white, educated, and empowered populations. Vulnerable and marginalized people are often deprived of opportunities to participate in clinical trials. Despite consistent endeavors by regulators, industry, and other stakeholders, factors including diversity in trial regulations and patient and provider-related cultural, logistic, and operational barriers limit the inclusiveness of clinical trials. Understanding and addressing these constraints by collaborative actions involving regulatory initiatives, industry, patient advocacy groups, community engagement in a culturally sensitive manner, and designing and promoting decentralized clinical trials are vital to establishing a clinical research ecosystem that promotes equity in the representation of population subgroups.

oncology
How patient-clinician education can strengthen partnerships and promote tangible actions to improve clinical trial diversity in breast and lung cancer trials.

Tariqa Ackbarali,Ricki Fairley,Susan Thomas Vadaparampil,Aaron Elliott Lisberg,Raymond U. Osarogiagbon,Monique Gary

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.6510

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:6510 Background: Some of the greatest disparities in cancer care are related to clinical trial access for our patients. To address the racial/ethnic disparities in breast and lung cancer clinical trials, a tethered educational initiative was designed to empower patients, assess current clinician perceptions/practices, and improve awareness of real-world perspectives of clinical trials. Methods: Two, one-hour online, interactive, video-based programs were designed for patients, caregivers, and providers. This patient/caregiver program was hosted on CancerCoachLive and MedLive in November, 2022, while the provider program was hosted on ClinicalSeriesLive in December, 2022 and will remain on-demand until December 2023. This initiative was conducted in collaboration with TOUCH, the Black Breast Cancer Alliance, BlackDoctors.org, Moffitt Cancer Center, CancerCare, and the Lung Cancer Research Foundation. Herein, we report on an analysis from patients and providers regarding clinical trial diversity, behavioral impact, and qualitative insights. Results: As of data cut-off (02/10/23), 1,425 participants have engaged across both educational programs. Of participating patients, 46% were non-White (non-Hispanic), 36% were in remission, 36% were not on active treatment, and 29% were newly diagnosed. Following the program 81% were motivated to take one or more actions over the next two months: the most common actions being to research clinical trials (38%) or discuss clinical trials with a clinician (19%). Post-activity, 79% were confident to very confident discussing clinical trials with a clinician. Critical data related to clinician preferences was assessed and demonstrated a 23% increase in confidence from pre- to post-activity in improving diversity in clinical trial participation with preferences observed in both breast and lung cancers to offer clinical trials for newly diagnosed and second recurrence settings. Of those who are being offered clinical trials in the community setting, there was a higher likelihood for patients to be offered a clinical trial if their subtype was HER2+ breast cancer subtype or NSCLC with an actionable mutation. Data collection continues as this initiative is ongoing. Qualitative data including clinician write-in examples of behavioral impact and patient perspectives from the interviews will be shared. Conclusions: The outcomes discussed herein reveal a willingness from patients/caregivers to engage in clinical trial discussions and participate in clinical trials, if eligible. These educational programs positively impacted clinician motivation to address barriers to enrollment and clinical trial eligibility with their patients. Real-world accounts of patient experiences provide different perspectives that can help improve approaches to improve clinical trial diversity.

oncology
How to make cardiology clinical trials more inclusive

Faiez Zannad,Otavio Berwanger,Stefano Corda,Martin R. Cowie,Habib Gamra,C. Michael Gibson,Alexandra Goncalves,Thomas Hucko,Kamlesh Khunti,Maciej Kostrubiec,Bettina Johanna Kraus,Cecilia Linde,Thomas F. Lüscher,Marion Mafham,Richard Mindham,Rebecca F. Ortega,Eva Prescott,Lehana Thabane,Clyde Yancy,André Ziegler,Harriette G. C. Van Spall

DOI: https://doi.org/10.1038/s41591-024-03273-3

IF: 82.9

2024-10-16

Nature Medicine

Abstract:Cardiovascular clinical trials continue to under-represent children, older adults, females and people from ethnic minority groups relative to population disease distribution. Here we describe strategies to foster trial representativeness, with proposed actions at the levels of trial funding, design, conduct and dissemination. In particular, trial representativeness may be increased through broad recruitment strategies and site selection criteria that reflect the diversity of patients in the catchment area, as well as limiting unjustified exclusion criteria and using pragmatic designs that minimize research burden on patients (including embedded and decentralized trials). Trial communications ought to be culturally appropriate; engaging diverse people with lived experience in the co-design of some trial elements may foster this. The demographics of trialists themselves are associated with participant demographics; therefore, trial leadership must be actively diversified. Funding bodies and journals increasingly require the reporting of sociodemographic characteristics of trial participants, and regulatory bodies now provide guidance on increasing trial diversity; these steps may increase the momentum towards change. Although this Perspective focuses on the cardiovascular trial context, many of these strategies could be applied to other fields.

biochemistry & molecular biology,cell biology,medicine, research & experimental
A successful clinical trial ecosystem offers equal opportunities for all citizens

Tarec Christoffer El‐Galaly,Anne Stidsholt Roug,Daniel Tuyet Kristensen

DOI: https://doi.org/10.1111/bjh.19927

2024-11-30

British Journal of Haematology

Abstract:An inclusive clinical trial ecosystem is essential to obtain scientific results that can be generalized to a broad patient population. When possible, all efforts should be made to remove geographic, demographic, cultural and ethnic barriers for enrolment in clinical trials. However, to do this effectively, we need more knowledge about factors influencing clinical trial participation and practical frameworks to enhance diversity in clinical trials. Commentary on: Jones et al. Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19907.

hematology
"First, Trust Needs to Develop": Hematologists' Perspectives on Factors Influencing Black Persons' Participation in Clinical Trials

Shakira J. Grant,Milenka Jean-Baptiste,Jiona A. Mills,Paul Mihas

DOI: https://doi.org/10.1007/s40615-024-02205-8

2024-10-19

Journal of Racial and Ethnic Health Disparities

Abstract:Cancer clinical trials are crucial for treatment standards and innovation but lack racial-ethnic diversity. Understanding physician perspectives on recruiting participants is critical due to their role in decision-making about trial candidacy and enrollment.

public, environmental & occupational health
Abstract 1311: Planning for health equity in oncology trials: Expectations and feasibility

Halcyon G. Skinner,Caroline Marra,April I. Alexandrow,Hamsa L. Subramaniam,Nathan C. Nussbaum,Joseph B. Franklin,Edgar P. Simard,Amy P. Abernethy

DOI: https://doi.org/10.1158/1538-7445.am2024-1311

IF: 11.2

2024-03-31

Cancer Research

Abstract:Achieving diverse representation in oncology studies is an ongoing challenge., Responding to calls to advance health equity in clinical trials, Congress amended the Food Drug and Cosmetic Act to require trial sponsors to submit a "diversity action plan" to the FDA with a study's protocol. This requirement to plan for diverse trial recruitment drives a need to innovate approaches for site selection and trial recruitment that go beyond mirroring race-ethnicity distributions from the US Census or disease prevalence. We present a novel framework that nests clinical trials in a longitudinal patient registry to achieve diverse representation across multiple domains, evaluate site-selection and recruitment strategies, and examine health equity across the cancer patient journey. Implementing a registry to support longitudinal data collection (i.e., a cohort study), we establish a continuous view of participant characteristics including demographic and social determinants of health, treatment received, and relevant outcomes. Nesting clinical trials within the structure of the cohort, we can select sites and recruit for diverse representation to achieve equity goals. This framework involves a multi-layer analysis of external population statistics and internal reference registry to gauge the pool of eligible participants and calibrate the sampling strategy and recruitment expectations to the realities of clinical representation. Moreover, where clinical representation differs from population statistics, the registry offers an opportunity to report benchmarks for diversity and compare to site-level and study-level realized enrollment and feasibility. In conclusion, the path to health equity in oncology trials depends on a capacity to ask and answer the right questions in planning. What specific aspects of diversity are we aiming to capture? How do these aspects impact outcomes? We advocate for a dynamic planning process that continuously reevaluates goals and strategies in the face of enrollment data and evolving population demographics. By utilizing a registry with longitudinal follow-up, we can set forth clear expectations, transparently report on the progress of inclusion efforts, and candidly address feasibility challenges. We present a structured framework for trial sponsors to not only comply with the forthcoming requirement for diversity action plans, but ultimately to advance the goal of equitable cancer care through research that truly reflects the complex intersectional diversity of those impacted by the disease. Citation Format: Halcyon G. Skinner, Caroline Marra, April I. Alexandrow, Hamsa L. Subramaniam, Nathan C. Nussbaum, Joseph B. Franklin, Edgar P. Simard, Amy P. Abernethy. Planning for health equity in oncology trials: Expectations and feasibility [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1311.

oncology
Community Engagement Strategies for Underrepresented Racial and Ethnic Populations

Folakemi T. Odedina,Mark L. Wieland,Kim Barbel-Johnson,Jennifer M. Crook

DOI: https://doi.org/10.1016/j.mayocp.2023.07.015

IF: 11.104

2024-01-04

Mayo Clinic Proceedings

Abstract:The representation of racial and ethnic minority populations in clinical trials continues to be a challenge despite mandates, good intentions, and concerted efforts by funding agencies, regulatory bodies, and researchers to close the clinical trials gap. A lack of diversity in research results in both continued disparities and poorer health outcomes. It is thus imperative that investigators understand and effectively address the challenges of clinical trials participation by underrepresented populations. In this paper, we expound on best practices for participatory research by clearly defining the community, highlighting the importance of proper identification and engagement of strong community partners, and exploring patient- and provider-level barriers and facilitators that require consideration. A clearer understanding of the balance of power between researchers and community partners is needed for any approach that addresses clinical trials representation. Unintended biases in study design and methods may continue to prevent racial and ethnic minority participants from taking part, and significant organizational changes are necessary for efficient and transparent relationships. Comprehensive community engagement in research includes dissemination of clinical trial results within and in partnership with community partners. Through careful deliberation and honest reflection, investigators, institutions, and community partners can develop the tailored blueprints of research collaborations essential for true equity in clinical trials.

medicine, general & internal
The Challenges and Opportunities in Clinical Trial Diversity Mistrust in the healthcare system is a significant barrier to recruitment

Lisa Bailey

DOI: https://doi.org/10.1016/j.drudis.2024.104210

IF: 8.369

2024-10-21

Drug Discovery Today

Abstract:Drug Discov Today . 2024 Oct 17:104210. doi: 10.1016/j.drudis.2024.104210. Online ahead of print. NO

pharmacology & pharmacy
Examining the Association Between DCT Solutions Use and Participant Diversity in Clinical Trials

Zachary Smith,Kenneth Getz

DOI: https://doi.org/10.1007/s43441-024-00659-w

2024-05-13

Therapeutic Innovation & Regulatory Science

Abstract:Whereas anecdotal reports suggest that the use of decentralized clinical trial (DCT) solutions can improve participant diversity in clinical trials there is no quantitative evidence to support such reports.

pharmacology & pharmacy,medical informatics
Enhancing diversity of clinical trial populations in multiple sclerosis

Ruth Ann Marrie,Jeremy Chataway,Barbara E Bierer,Marcia Finlayson,Elena H Martinez-Lapiscina,Jennifer Panagoulias,Maria Pia Sormani,Mitzi Joi Williams,Lilyana Amezcua

DOI: https://doi.org/10.1177/13524585231189677

Abstract:Background: Demographic characteristics, social determinants of health (SDoH), health inequities, and health disparities substantially influence the general and disease-specific health outcomes of people with multiple sclerosis (MS). Participants in clinical trials do not represent all people with MS treated in practice. Objective: To provide recommendations for enhancing diversity and inclusion in clinical trials in MS. Methods: We held an international workshop under the Auspices of the International Advisory Committee on Clinical Trials in MS (the "Committee") to develop recommendations regarding diversity and inclusivity of participants of clinical trials in MS. Workshop attendees included members of the Committee as well as external participants. External participants were selected based on expertise in trials, SDoH, health equity and regulatory science, and diversity with respect to gender, race, ethnicity, and geography. Results: Recommendations include use of diversity plans, community engagement and education, cultural competency training, biologically justified rather than templated eligibility criteria, adaptive designs that allow broadening of eligibility criteria over the course of a trial, and logistical and practical adjustments to reduce study participant burden. Investigators should report demographic and SDoH characteristics of participants. Conclusion: These recommendations provide sponsors and investigators with methods of improving diversity and inclusivity of clinical trial populations in MS.
Recommendations to promote equity, diversity and inclusion in decentralized clinical trials

Olalekan Lee Aiyegbusi,Samantha Cruz Rivera,Paul Kamudoni,Nicola Anderson,Philip Collis,Alastair K. Denniston,Rosie Harding,Sarah E. Hughes,Kamlesh Khunti,Dipak Kotecha,Harlan Krumholz,Xiaoxuan Liu,Christel McMullan,Barbara Molony-Oates,Joao Monteiro,Puja Myles,Khadija Rerhou Rantell,Katherine Soltys,Ravinder Verdi,Roger Wilson,Melanie J. Calvert

DOI: https://doi.org/10.1038/s41591-024-03323-w

IF: 82.9

2024-10-30

Nature Medicine

Abstract:Decentralized clinical trials involving the use of digital tools to facilitate remote research are gaining momentum. Rapid advancements in digital technologies have supported the adoption of these trials. These innovations facilitate virtual interactions between clinical trial teams and participants by making it easier to collect, transfer and store electronic data. While some studies have demonstrated the potential for these approaches to reduce barriers to clinical trial participation, they are associated with several challenges that may create or worsen existing health inequalities and limit the generalizability of trial results. Here we review the potential for digitally enabled and decentralized clinical trials to enhance clinical trial participation in an equitable manner. We describe the key barriers individuals from underserved groups may face, and provide recommendations to promote equity, diversity and inclusion.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Promoting equity in clinical research: The role of social determinants of health

Betina Idnay,Yilu Fang,Edward Stanley,Brenda Ruotolo,Wendy K Chung,Karen Marder,Chunhua Weng

DOI: https://doi.org/10.1016/j.jbi.2024.104663

Abstract:Objective: This study aims to investigate the association between social determinants of health (SDoH) and clinical research recruitment outcomes and recommends evidence-based strategies to enhance equity. Materials and methods: Data were collected from the internal clinical study manager database, clinical data warehouse, and clinical research registry. Study characteristics (e.g., study phase) and sociodemographic information were extracted. Median neighborhood income, distance from the study location, and Area Deprivation Index (ADI) were calculated. Mixed effect generalized regression was used for clustering effects and false discovery rate adjustment for multiple testing. A stratified analysis was performed to examine the impact in distinct medical departments. Results: The study sample consisted of 3,962 individuals, with a mean age of 61.5 years, 53.6 % male, 54.2 % White, and 49.1 % non-Hispanic or Latino. Study characteristics revealed a variety of protocols across different departments, with cardiology having the highest percentage of participants (46.4 %). Industry funding was the most common (74.5 %), and digital advertising and personal outreach were the main recruitment methods (58.9 % and 90.8 %). Discussion: The analysis demonstrated significant associations between participant characteristics and research participation, including biological sex, age, ethnicity, and language. The stratified analysis revealed other significant associations for recruitment strategies. SDoH is crucial to clinical research recruitment, and this study presents evidence-based solutions for equity and inclusivity. Researchers can tailor recruitment strategies to overcome barriers and increase participant diversity by identifying participant characteristics and research involvement status. Conclusion: The findings highlight the relevance of clinical research inequities and equitable representation of historically underrepresented populations. We need to improve recruitment strategies to promote diversity and inclusivity in research.
Health Disparities, Clinical Trials, and the Digital Divide

Demilade Adedinsewo,Lauren Eberly,Olayemi Sokumbi,Jorge Alberto Rodriguez,Christi A Patten,LaPrincess C Brewer

DOI: https://doi.org/10.1016/j.mayocp.2023.05.003

Abstract:In the past few years, there have been rapid advances in technology and the use of digital tools in health care and clinical research. Although these innovations have immense potential to improve health care delivery and outcomes, there are genuine concerns related to inadvertent widening of the digital gap consequentially exacerbating health disparities. As such, it is important that we critically evaluate the impact of expansive digital transformation in medicine and clinical research on health equity. For digital solutions to truly improve the landscape of health care and clinical trial participation for all persons in an equitable way, targeted interventions to address historic injustices, structural racism, and social and digital determinants of health are essential. The urgent need to focus on interventions to promote health equity was made abundantly clear with the coronavirus disease 2019 pandemic, which magnified long-standing social and racial health disparities. Novel digital technologies present a unique opportunity to embed equity ideals into the ecosystem of health care and clinical research. In this review, we examine racial and ethnic diversity in clinical trials, historic instances of unethical research practices in biomedical research and its impact on clinical trial participation, and the digital divide in health care and clinical research, and we propose suggestions to achieve digital health equity in clinical trials. We also highlight key digital health opportunities in cardiovascular medicine and dermatology as exemplars, and we offer future directions for development and adoption of patient-centric interventions aimed at narrowing the digital divide and mitigating health inequities.

Why diversity is needed at every level of clinical trials, from participants to leaders

Enhancing Diversity and Inclusion in Clinical Trials

On improving clinical trial diversity: Viewpoints from underrepresented breast cancer survivors.

Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representatives

Diversity, Equity, and Inclusion in Clinical Research: A Path Toward Precision Health for Everyone

Inclusion and diversity in clinical trials: Actionable steps to drive lasting change

Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel

Clinical Trial Access in Diverse Populations

Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers

How patient-clinician education can strengthen partnerships and promote tangible actions to improve clinical trial diversity in breast and lung cancer trials.

How to make cardiology clinical trials more inclusive

A successful clinical trial ecosystem offers equal opportunities for all citizens

"First, Trust Needs to Develop": Hematologists' Perspectives on Factors Influencing Black Persons' Participation in Clinical Trials

Abstract 1311: Planning for health equity in oncology trials: Expectations and feasibility

Community Engagement Strategies for Underrepresented Racial and Ethnic Populations

The Challenges and Opportunities in Clinical Trial Diversity Mistrust in the healthcare system is a significant barrier to recruitment

Examining the Association Between DCT Solutions Use and Participant Diversity in Clinical Trials

Enhancing diversity of clinical trial populations in multiple sclerosis

Recommendations to promote equity, diversity and inclusion in decentralized clinical trials

Promoting equity in clinical research: The role of social determinants of health

Health Disparities, Clinical Trials, and the Digital Divide